Clinical Background

Cytomegalovirus (CMV) infection following hematopoietic stem cell transplantation (HCT) is a major complication that significantly increases mortality. Currently, antiviral prophylaxis such as letermovir is employed, but the risk of re‑infection persists after discontinuation of therapy. Understanding this context underscores the need for a preventive vaccine.

Vaccine Mechanism

mRNA-1647 is an mRNA vaccine that expresses multiple CMV antigens simultaneously, enabling the immune system to recognize a broad antigenic repertoire and induce durable protection. By directing intracellular production of viral proteins, mRNA vaccines elicit immune responses that resemble natural infection. This approach offers faster manufacturing and greater adaptability to viral variants compared to traditional protein‑based vaccines.

Study Design

This Phase 2 study compares mRNA-1647 with placebo to assess the incidence of clinically significant CMV infection (CS‑CMVi). The primary endpoint is the occurrence of infection after cessation of CMV prophylaxis, measured from day 100 to month 9 post‑HCT. The trial is currently in an ACTIVE_NOT_RECRUITING status and was initiated on 2023‑04‑05.

Differentiation from Current Therapy

The current standard of care consists of antiviral agents such as letermovir, which leave patients vulnerable to re‑infection after therapy discontinuation. mRNA-1647 aims to pre‑emptively boost immunity to prevent re‑infection, offering the potential to be used alongside or in place of existing prophylaxis. Success could substantially shift the CMV management paradigm.

Industry Impact

CMV is estimated to cause several thousand deaths annually among HCT patients. Approval of the vaccine would enable Moderna to expand an mRNA vaccine portfolio distinct from biosimilars. This would serve as a pivotal example that mRNA technology can be applied not only to infectious diseases but also to prophylaxis in immunocompromised populations.